Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Feb 3, 2023
- Accession no.
- 0001209191-23-007041
- Filed
- Feb 3, 2023
- Trade date
- Feb 1-2, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 11 non-derivative transactions and 5 derivative transactions. Open-market sales total $193.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | Class A Common Stock | AGrant or awardAcquired | +406,800 | $0.00 | $0 | 932,605 | Direct | |
| Feb 1, 2023 | Class A Common Stock | AGrant or awardAcquired | +11,050 | $0.00 | $0 | 943,655 | Direct | |
| Feb 1, 2023 | Class A Common Stock | FTax withholdingDisposed | −1,382 | $8.55 | −$11,816.1 | 942,273 | Direct | |
| Feb 2, 2023 | Class A Common Stock | CConversionAcquired | +18,500 | $0.00 | $0 | 960,773 | Direct | |
| Feb 2, 2023 | Class A Common Stock | SSaleDisposed | −18,500 | $9.22F6 | −$170,570 | 942,273 | Direct | |
| Feb 2, 2023 | Class A Common Stock | CConversionAcquired | +500 | $0.00 | $0 | 500 | Indirect | |
| Feb 2, 2023 | Class A Common Stock | SSaleDisposed | −500 | $9.21F8 | −$4,605 | 0 | Indirect | |
| Feb 2, 2023 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Feb 2, 2023 | Class A Common Stock | SSaleDisposed | −1,000 | $9.21F10 | −$9,210 | 0 | Indirect | |
| Feb 2, 2023 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Feb 2, 2023 | Class A Common Stock | SSaleDisposed | −1,000 | $9.20F12 | −$9,200 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | Class A Common Stock | AGrant or awardAcquired | +813,600 | $0.00 | $0 | 813,600 | Direct | |
| Feb 2, 2023 | Class A Common Stock | CConversionDisposed | −18,500 | $0.00 | $0 | 6,640,334 | Direct | |
| Feb 2, 2023 | Class A Common Stock | CConversionDisposed | −500 | $0.00 | $0 | 539,500 | Indirect | |
| Feb 2, 2023 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 529,000 | Indirect | |
| Feb 2, 2023 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 125,875 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F6
This transaction was executed in multiple trades at prices ranging from $8.63 to $9.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F8
This transaction was executed in multiple trades at prices ranging from $8.63 to $9.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $8.66 to $9.52 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F12
This transaction was executed in multiple trades at prices ranging from $8.64 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.